X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will support the continuation of the ongoing research collaboration between Aegis Life and Entos Pharmaceuticals, developing novel DNA-based encoded antibody therapeutics against HIV and malaria using the Entos Fusogenix PLV nucleic acid delivery technology.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Aegis Life
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Financing March 19, 2024
Details:
The net proceeds will be used to advance Sail’s first-in-category Endless RNA™ platform for preclinical development of an eRNA-based vaccines and to develop secreted monoclonal antibodies (mAbs) for malaria.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Sail Biomedicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 03, 2024
Details:
The funding aims to support Radiant to develop the next generation of HIV biologics based on Radiant’s Multabody platform, which can destroy latent stores of the HIV virus, along with its ability to eliminate circulating viral particles.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Radiant Biotherapeutics
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 20, 2023
Details:
The net proceeds will be used to conduct a Phase IIb trial assessing the safety and efficacy of the tuberculosis (TB) vaccine candidate MTBVAC to prevent active TB lung disease in adolescents and adults.
Lead Product(s): MTBVAC
Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC
Highest Development Status: Phase IIIProduct Type: Vaccine
Recipient: IAVI
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 18, 2023
Details:
The financing will be used to develop a novel live cell therapeutic that can produce antibodies to fight human immunodeficiency virus (HIV) and/or malaria directly in the body.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Ginkgo Bioworks
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding December 13, 2023
Details:
The company will develop its proprietary single shot, thermostabilization vaccine technology (ALTA™) and will study the ALTA™ mechanism of action using model antigens, such as those targeting HIV.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: VitriVax
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding December 06, 2023
Details:
The funding will support the discovery of novel inhibitors of aminoacyl-tRNA synthetases using AN2’s proprietary boron chemistry platform for the treatment of tuberculosis and malaria.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: AN2 Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 26, 2023
Details:
This program is evaluating two novel drug regimens comprising five antibacterial agents—bedaquiline, delamanid, pretomanid, quabodepistat (formerly known as OPC-167832), and sutezolid.
Lead Product(s): Delamanid,Bedaquiline,OPC-167832
Therapeutic Area: Infections and Infectious Diseases Product Name: Deltyba
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Otsuka Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
The expanded collaboration is expected to deliver more than 320 million doses of Pfizer’s injectable contraceptive, Sayana Press (medroxyprogesterone acetate) administered by BD Uniject™ Auto-Disable Prefillable Injection System, through 2030.
Lead Product(s): Medroxyprogesterone Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Sayana Press
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration August 03, 2023
Details:
The funding will advance a TB vaccine candidate, M72, through a Phase III trial. The AS01E vaccine candidate contains the M72 recombinant fusion protein, which is derived from two Mycobacterium tuberculosis antigens, combined with the GSK proprietary Adjuvant System AS01E.
Lead Product(s): AS01E
Therapeutic Area: Infections and Infectious Diseases Product Name: GSK692342
Highest Development Status: Phase IIProduct Type: Vaccine
Recipient: GSK
Deal Size: $550.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 28, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
